Clinical Trial

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

Study acronym: PED-DNX2401
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401. The main questions it aims to answer are: * Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival? * Is a single intratumoral administration of DNX-2401 safe and well tolerated? Participants will: * Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401 * Visit the clinic periodically for checkups and tests
Protocol Amendment History 4 changes
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-05-28
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-05-16
notable Primary completion pushed: 2029-04 -> 2029-05 2026-05-16
minor Completion pushed: 2029-04 -> 2029-05 2026-05-16
Trial Details
NCT Number NCT07424092
Lead Sponsor Clinica Universidad de Navarra, Universidad de Navarra
Collaborators: Princess Maxima Center for Pediatric Oncology, Asociación Española contra el Cáncer
Conditions High Grade Glioma, Ependymoma, Embryonal Tumor of Brain, Recurrence, Refractory, Pediatric, Young Adult
Enrollment 39 participants
Start Date 2026-05-12
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-27